We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Suggests 28-Day Goal for cIAI Clinical Trials
Draft Guidance Suggests 28-Day Goal for cIAI Clinical Trials
October 10, 2012
Clinical trials of drugs to treat complicated intra-abdominal infections (cIAI) should have a primary endpoint of complete resolution of symptoms at 28 days following randomization and the absence of clinical failure, according to an FDA draft guidance.